FOLEY & LARDNER

ATTORNEYS AT LAW WASHINGTON HARBOUR 3000 K STREET, N.W., SUITE 500 WASHINGTON, D.C. 20007-5109 TELEPHONE: (202) 672-5300 FAÇŞIMILE: (202) 672-5399

FAX RECEIVED JUL 0 % 5005

# FACSIMILE TRANSMISSION GROUP 1600

Total # of Pages 2	2 (including this page)	L'E HOHA	
то:	PHONE:	FAX #:	
Examiner Christopher H. Yaen	(702) 205 2506	(703) 308 4242	
U.S. Patent & Trademark Office	(703) 305 3586		

From: Stephen B. Maebius

Sender's Direct Dial: (202) 672-5569

Date: July 1, 2002

018733/1055 Client/Matter No:

User ID No: 0473

Serial No. 09/924,103

Applicants: David M. Goldenberg et al.

Filed: August 8, 2001

Entitled: Immunotherapy for Chronic Myelocytic

Leukemia

### MESSAGE:

### **Certificate of Transmission**

I hereby certify that a Response to Restriction Requirement is being facsimile transmitted to the

Patent and Trademark Office on July 1, 2002.

Date:

Stephen B. Maebius

Registration No. 35,264

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.



JUL 0 > 2002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE GROUP 1600

Attorney Docket No. 018733-1055

In re patent application of

David M. Goldenberg, et al.

Serial No. 09/924,103

Filed: August 8, 2001

For:

Group Art Unit: 1642

Examiner: Christopher H. Yaen

IMMUNOTHERAPY FOR CHRONIC MYELOTIC LEUKEMIA

### SUPPLEMENTAL RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the communication mailed on June 4, 2002, in which the Examiner pointed out the additional requirement to elect a species within Group I contained in the originally mailed restriction requirement, applicants elect hMN-3 in humanized form. Receipt of the initial Office Action on the merits is awaited.

Respectfully submitted,

July 1, 2002

Date

Stephen B. Maebius

Reg. No. 35,264

#### FOLEY & LARDNER

3000 K Street, N.W., Suite 500

Washington, D.C. 20007-5109

Telephone:

(202) 672-5300

Facsimile:

(202)672-5399

Shovids delign thes demeses any surconnection with the triangular state of the mention of the ention of the entire entire